T
Toru Mukohara
Researcher at Kobe University
Publications - 99
Citations - 3005
Toru Mukohara is an academic researcher from Kobe University. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 19, co-authored 69 publications receiving 2466 citations.
Papers
More filters
Journal ArticleDOI
Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer
Yoshinori Imamura,Toru Mukohara,Yohei Shimono,Yohei Funakoshi,Naoko Chayahara,Masanori Toyoda,Naomi Kiyota,Shintaro Takao,Seishi Kono,Tetsuya Nakatsura,Hironobu Minami +10 more
TL;DR: 3D- Cultured cells forming dense MCSs may be better than 2D-cultured cells in simulating important tumor characteristics in vivo, namely hypoxia, dormancy, anti-apoptotic features and their resulting drug resistance.
Journal ArticleDOI
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.
Jeffrey A. Engelman,Pasi A. Jänne,Craig H. Mermel,Joseph Pearlberg,Toru Mukohara,Christina Fleet,Karen Cichowski,Bruce E. Johnson,Lewis C. Cantley +8 more
TL;DR: ErbB-3 is used to couple EGFR to the PI3K/Akt pathway in gefitinib-sensitive NSCLC cell lines harboring WT and mutant EGFRs, and dissociates this complex, thereby linking EGFR inhibition to decreased Akt activity.
Journal ArticleDOI
Gefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255
TL;DR: A mechanism by which gefitinib treatment of NSCLC harboring EGFRL858R leads to a dramatic response to gef itinib is characterized.
Journal ArticleDOI
Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines
TL;DR: Growth inhibition by trastuzumab and CL-387,785 was more closely correlated with changes in phosphorylation of S6K than those of HER2, Akt, or ERK1/2.
Journal ArticleDOI
PI3K mutations in breast cancer: prognostic and therapeutic implications
TL;DR: There is currently no sufficient evidence to recommend routine genotyping of PIK3CA in clinical practice, and development of more individualized targeted therapies based on the Pik3CA genotype is awaited.